Cartesian Therapeutics Inc (RNAC) Price Prediction & ForecastRNACCartesian Therapeutics Inc

Alphio's RNAC stock price prediction model matches the current Cartesian Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $9.62 (+0.21%). The 1-week path is $9.56 (-0.38%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Cartesian Therapeutics Inc is a good buy right now due to its recent strategic licensing deal that has driven the stock up over 30%, indicating strong market confidence. The current price is $9.60, which is significantly lower than the analyst price target of $25, suggesting substantial upside potential. Additionally, the company has a gross margin of 100%, showing strong profitability potential on revenues. However, a key risk is the forward P/E ratio of 25.06, indicating that the stock may be overvalued relative to its earnings potential in the near term.

Cartesian Therapeutics Inc (RNAC) last closed at $9.6, losing -3.71%. These facts feed the 1-day and 1-week RNAC price prediction above.